| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
7 companies
Patrick G Enright is Director, 10% Owner at MANE and has filed Form 4s across 7 companies. From March 2015 to August 2026, the filings on record show 9 open-market purchases and 22 sales. Patrick G Enright's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $301.5M at current prices.
Historically, Patrick G Enright's trades have earned a strong insider score of 71/100 across 13 rated trades. Over a 12-month horizon, 70.0% of those trades were profitable, with an average 12-month return of +11.7%.
The biggest single holding is MANE (~$274.4M) as Director, 10% Owner. Net of sales, the MANE filings show accumulation of 1,075,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 19, 2015 | ESPR Esperion Therapeutics, Inc. | Director | Sell | 500,000 | $111.66 | $55,831,597.19 | -96.5% |